TY - JOUR
T1 - Variability of bioavailability and intestinal absorption mechanisms of metoprolol
AU - Fukao, Miki
AU - Ishida, Kazuya
AU - Horie, Asuka
AU - Taguchi, Masato
AU - Nozawa, Takashi
AU - Inoue, Hiroshi
AU - Hashimoto, Yukiya
N1 - Funding Information:
Received May 15, 2013; Accepted August 29, 2013 J-STAGE Advance Published Date: September 10, 2013, doi:10.2133/dmpk.DMPK-13-RG-057 *To whom correspondence should be addressed: Yukiya HASHIMOTO, Ph.D., Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. Tel. © 81-76-434-7585, E-mail: yukiya@pha.u-toyama.ac.jp This work was supported in part by Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Sciences (JSPS) and from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.
PY - 2014
Y1 - 2014
N2 - We previously reported that aging and/or cytochrome P450 2D6 polymorphism are responsible for the interindividual variability in the systemic clearance (CL) and bioavailability (F) of metoprolol. The aim of the present study was to evaluate the residual variability of F of metoprolol in routinely treated Japanese patients and to investigate the intestinal absorption mechanism of the drug using human intestinal epithelial LS180 cells. We first re-analyzed the blood concentration data for metoprolol in 34 Japanese patients using a nonlinear mixed effects model. The oral clearance (CL/F) of metoprolol was positively correlated with the apparent volume of distribution (V/F), suggesting the residual variability of F. The uptake of metoprolol into LS180 cells was significantly decreased by the acidification of extracellular medium pH, and was dependent on temperature and intracellular pH. Furthermore, the cellular uptake of metoprolol was saturable, and was significantly decreased in the presence of hydrophobic cationic drugs such as diphenhydramine, procainamide, bisoprolol, and quinidine. These findings indicate that residual variability of F is one of the causes of the interindividual pharmacokinetic variability of metoprolol, and that the interindividual variability of not only presystemic first-pass metabolism, but also intestinal absorption, may be responsible for the variable F of the drug.
AB - We previously reported that aging and/or cytochrome P450 2D6 polymorphism are responsible for the interindividual variability in the systemic clearance (CL) and bioavailability (F) of metoprolol. The aim of the present study was to evaluate the residual variability of F of metoprolol in routinely treated Japanese patients and to investigate the intestinal absorption mechanism of the drug using human intestinal epithelial LS180 cells. We first re-analyzed the blood concentration data for metoprolol in 34 Japanese patients using a nonlinear mixed effects model. The oral clearance (CL/F) of metoprolol was positively correlated with the apparent volume of distribution (V/F), suggesting the residual variability of F. The uptake of metoprolol into LS180 cells was significantly decreased by the acidification of extracellular medium pH, and was dependent on temperature and intracellular pH. Furthermore, the cellular uptake of metoprolol was saturable, and was significantly decreased in the presence of hydrophobic cationic drugs such as diphenhydramine, procainamide, bisoprolol, and quinidine. These findings indicate that residual variability of F is one of the causes of the interindividual pharmacokinetic variability of metoprolol, and that the interindividual variability of not only presystemic first-pass metabolism, but also intestinal absorption, may be responsible for the variable F of the drug.
KW - Bioavailability
KW - Intestinal absorption
KW - LS180 cell
KW - Metoprolol
KW - Nonlinear mixed effects model (NONMEM)
UR - http://www.scopus.com/inward/record.url?scp=84901241380&partnerID=8YFLogxK
U2 - 10.2133/dmpk.DMPK-13-RG-057
DO - 10.2133/dmpk.DMPK-13-RG-057
M3 - 学術論文
C2 - 24025984
AN - SCOPUS:84901241380
SN - 1347-4367
VL - 29
SP - 162
EP - 167
JO - Drug Metabolism and Pharmacokinetics
JF - Drug Metabolism and Pharmacokinetics
IS - 2
ER -